top of page
The Professional Network for Healthcare Experts
Genentech licenses Alector brain-penetrant Parkinson's programme in deal worth up to $1.27bn
Genentech has licensed Alector's brain-penetrant AL050 programme in a neurodegeneration deal worth up to $1.27 billion.
nuaxia
Oct 62 min read
FDA approves Gazyva for idiopathic nephrotic syndrome in patients aged two years and older
The FDA has approved Gazyva for patients aged two years and older with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome who are in complete remission.
nuaxia
Oct 12 min read
Roche’s Genentech licenses Hanmi obesity candidate HM17321 in deal worth up to $2.3 billion
The agreement gives Genentech ex-South Korea rights to a Phase I non-incretin UCN2 analogue designed to reduce weight while preserving lean body mass, adding a differentiated mechanism to Roche’s growing cardiometabolic pipeline.
nuaxia
Aug 253 min read
bottom of page